During the United European Gastroenterology Week 2019 meeting, held in Barcelona, Spain, researchers presented results of a phase 1 pivotal study of a subcutaneously administered formulation of biosimilar infliximab, CT-P13 (Remsima, Inflectra), in patients with inflammatory bowel disease (IBD).
In September, Republic of Korea-based biosimilar developer Celltrion received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use for its subcutaneous formulation of biosimilar infliximab, CT-P13 (Remsima, Inflectra), for the treatment of rheumatoid arthritis, and final authorization from the European Commission is expected in the coming weeks.
The biosimilar developer has also been investigating the novel formulation of the product in inflammatory bowel disease (IBD), and this week, during the United European Gastroenterology Week 2019 meeting, held in Barcelona, Spain, researchers presented results of a phase 1 pivotal study of the product in patients with IBD.
The findings, presented in a late-breaking abstract session, show that the subcutaneously administered biosimilar was noninferior to the intravenously administered version at week 22, and had comparable safety and efficacy up to week 30.
In the study, 136 patients with either Crohn disease (CD) or ulcerative colitis (UC) were given loading doses of intravenous CT-P13, at a dose of 5 mg per kg, at weeks 0 and 2. Then, they were randomized at week 6 to either receive a subcutaneous dose of 120 mg or 240 mg every 2 weeks, or to receive intravenous therapy at 5 mg per kg every 8 weeks. The primary endpoint was trough concentration at week 22. Noninferiority was prespecified as the lower bound of the 2-sided 90% confidence interval (CI) for the ratio of the geometric least squares mean being higher than 80%.
The lower bound of the 90% CI was greater than 80% at week 22, with higher geometric LS mean of trough concentration in the subcutaneous administration arm, and the researchers note that “Frequent administration of small doses and delayed absorption of [subcutaneous CT-P13] led to more constant exposure compared to [intravenous] dosing."
With respect to efficacy up to week 30, clinical response and remission were both induced and maintained and were comparable in both treatment arms. The combined clinical remission rates for patients with CD and UC at week 30 were comparable between the subcutaneous and intravenous arms, respectively (66.7% vs 54.7%; P = .1620).
Injection site reactions (ISRs) occurred more commonly in the subcutaneous arm, but all ISRs were grade 1 or 2 in intensity, and the safety profiles of the 2 CT-P13 products were generally similar. The incidence of antidrug antibodies was slightly lower in subcutaneous group at week 30 than in the intravenous group (37.9% vs 3.8%).
“CT-P13 [subcutaneous] infliximab has the potential to become the most innovative biosimilar treatment—improving convenience and allowing patients to have more control of their treatment in addition to direct clinical benefits,” said Stefan Schreiber, MD, PhD, director of the Clinic for Internal Medicine at Kiel Campus of the University Hospital Schleswig-Holstein in Germany, and first author of the study. “Not without reason the [intravenous/subcutaneous] sequence therapy that has been implemented into most development paths for novel molecules.”
In a statement, Celltrion noted that it plans to file for European regulatory approval for the subcutaneous formulation in IBD during the second half of 2020.
Reference
Schreiber S, Leszczyszyn J, Dudkowiak R, et al. Noninferiority of novel subcutaneous infliximab (CT-P13) to intravenous infliximab (CT-P13) in patients with active Crohn’s disease and ulcerative colitis: week 30 results form a multicenter, randomized controlled pivotal trial. Presented at: United European Gastroenterology Week 2019; October 29-23, 2019; Barcelona, Spain.
Eye on Pharma: BI Cyltezo Partnership; Europe Ustekinumab Launch; Mexico Biosimilar Approval
July 24th 2024Boehringer Ingelheim (BI) partners with GoodRx to offer its unbranded adalimumab biosimilar to patients at an exclusive low price; a new ustekinumab biosimilar launches in Europe; and Mexican officials approve a bevacizumab biosimilar.
Biosimilars Gastroenterology Roundup for May 2024—Podcast Edition
June 2nd 2024On this episode of Not So Different, we review the biggest gastroenterology biosimilar stories from May 2024, covering new data from conferences and journals on infliximab and adalimumab products that demonstrate positive clinical results and confirm the safety of these biosimilars, as well as the feasibility of switching to them.
Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report
May 19th 2024The discussion highlights key emerging trends from the Festival of Biologics conference and the annual Cardinal Health Biosimilars Report, including the importance of sustainability in the health care landscape and the challenges and successes in biosimilar adoption and affordability.
Phase 3 Trials Find Subcutaneous Infliximab CT-P13 Superior to Placebo in IBD
June 29th 2024Two phase 3 trials in patients with inflammatory bowel disease (IBD) found higher clinical remission rates in those treated with the subcutaneous formulation of infliximab biosimilar CT-P13 compared with placebo as maintenance therapy following an induction phase of intravenous CT-P13.
Biosimilar Adoption in the UK: Patient and Consultant Views on Safety and Switching
June 26th 2024Lack of knowledge and confidence in biosimilars continues despite growing education efforts, impacting provider willingness to prescribe biosimilar medicines and patient perceptions about their treatment and switching to a biosimilar.